NCT06156280

A Clinical Study of TQH2929 in Healthy Adult Subjects

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of TQH2929 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This project is divided into a single dose escalation and a multiple dose escalation phase Ia clinical study. This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQH2929 injection in healthy adults.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	TQH2929 injection	TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
DRUG	Placebo injection	Placebo comparator

Timeline

• Start date: 2023-11-21
• Primary completion: 2024-08-02
• Completion: 2025-03-21
• First posted: 2023-12-05
• Last updated: 2025-03-25

Locations

1 site across 1 country: China